PMID- 28420034
OWN - NLM
STAT- MEDLINE
DCOM- 20171006
LR  - 20191210
IS  - 1098-2264 (Electronic)
IS  - 1045-2257 (Linking)
VI  - 56
IP  - 8
DP  - 2017 Aug
TI  - A fluorescence in situ hybridization-based screen allows rapid detection of 
      adverse cytogenetic alterations in patients with acute myeloid leukemia.
PG  - 632-638
LID - 10.1002/gcc.22466 [doi]
AB  - In adult acute myeloid leukemia (AML), the karyotype of the leukemic cell is 
      among the strongest prognostic factors. The Medical Research Council (MRC) and 
      the European LeukemiaNet (ELN) classifications distinguish between favorable, 
      intermediate and adverse cytogenetic risk patients who differ in their treatment 
      response and overall survival. Conventional cytogenetic analyses are a mandatory 
      component of AML diagnostics but they are time-consuming; therefore, therapeutic 
      decisions in elderly patients are often delayed. We investigated whether a 
      screening approach using a panel of seven fluorescence in situ hybridization 
      (FISH) probes would allow rapid identification of adverse chromosomal changes. In 
      a cohort of 334 AML patients, our targeted FISH screening approach identified 80% 
      of adverse risk AML patients with a specificity of 99%. Incorporating FISH 
      screening into diagnostic workup has the potential to accelerate risk 
      stratification and treatment selection, particularly in older patients. This 
      approach may allow therapeutic decisions more quickly, which benefits both 
      patients and physicians and might save costs.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Sandhofer, Nadine
AU  - Sandhofer N
AUID- ORCID: 0000-0003-1906-0655
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Metzeler, Klaus H
AU  - Metzeler KH
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Kakadia, Purvi M
AU  - Kakadia PM
AD  - Department of Molecular Medicine and Pathology, University of Auckland, New 
      Zealand.
FAU - Pasalic, Zlatana
AU  - Pasalic Z
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Hiddemann, Wolfgang
AU  - Hiddemann W
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Neusser, Michaela
AU  - Neusser M
AD  - Institute of Human Genetics, University Hospital, Ludwig-Maximilians-University, 
      Munich, Germany.
FAU - Steinlein, Ortrud
AU  - Steinlein O
AD  - Institute of Human Genetics, University Hospital, Ludwig-Maximilians-University, 
      Munich, Germany.
FAU - Fiegl, Michael
AU  - Fiegl M
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Subklewe, Marion
AU  - Subklewe M
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Spiekermann, Karsten
AU  - Spiekermann K
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Bohlander, Stefan K
AU  - Bohlander SK
AD  - Department of Molecular Medicine and Pathology, University of Auckland, New 
      Zealand.
FAU - Schneider, Stephanie
AU  - Schneider S
AD  - Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Braess, Jan
AU  - Braess J
AD  - Department of Oncology and Hematology, Hospital Barmherzige Bruder, Regensburg, 
      Germany.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20170519
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis/*methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Karyotype
MH  - Leukemia, Promyelocytic, Acute/diagnosis/*genetics
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
EDAT- 2017/04/19 06:00
MHDA- 2017/10/07 06:00
CRDT- 2017/04/19 06:00
PHST- 2016/09/04 00:00 [received]
PHST- 2017/04/11 00:00 [revised]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2017/10/07 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 10.1002/gcc.22466 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. Epub 
      2017 May 19.